Effects of Polydeoxyribonucleotide ( PDRN ) on Endosinus Bone Regeneration Following Sinus Floor Elevation: An Experimental In Vivo Pilot Study
Clinical Oral Implants Research · 2025-02 · 36 (2) · 239-249
DOI: 10.1111/clr.14378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Oral Implants Research, online erschienen am 19.11.2024. Verfasst von Hyunwoo Lim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dentistry, Graduate School, Kyung Hee University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Bone Regeneration, Sinus Floor Augmentation, Polydeoxyribonucleotides, Maxillary Sinus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Objective
To determine the effect of polydeoxyribonucleotide (PDRN) on endosinus bone regeneration in a rabbit sinus model at sequential healing time points. Materials and Methods Eighteen New Zealand white rabbits were used. Bilateral sinus floor elevation (SFE) was performed. Two groups were randomly assigned to each sinus: (1) test group, in which SFE was performed using collagenated bone substitute material soaked with PDRN (concentration 2.0 mg/mL, dose 0.5 mL), and (2) control group, in which SFE was performed using collagenated bone substitute material only. The experimental animals were sacrificed at 2, 4, and 8 weeks ( n = 6 at each healing time point). Microcomputed tomography (micro‐CT), histologic, and histomorphometric analyses were performed.
Results
The micro‐CT analysis revealed statistically significant increases in the mineralized tissue volume between 4 and 8 weeks ( p < 0.05). Histologically, no specific intergroup difference was found in the pattern of new bone formation. Histomorphometrically, the area of newly formed bone (NB) was larger in the test group than in the control group at all healing time points (1.4 vs. 1.2 mm 2 at 2 weeks, 3.4 vs. 1.9 mm 2 at 4 weeks, and 5.7 vs. 4.5 mm 2 at 8 weeks; median value), but the difference was statistically significant only at 4 weeks ( p < 0.05). NB in set regions of interest (ROI_C, ROI_W, and ROI_M) tended to be greater in the test group than in the control group without statistical significance ( p > 0.05).
Conclusions
PDRN appeared to enhance new bone formation at all healing time points, but the improvement was statistically significant only at 4 weeks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dentistry, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
- Department of Periodontology, Kyung Hee University College of Dentistry, Periodontal-Implant Clinical Research Institute, Kyung Hee University Medical Center, Seoul, Republic of Korea.
- Clinic of Reconstructive Dentistry, University of Zurich, Zurich, Switzerland.
ORCID-Profile: Daniel S Thoma, Ronald E Jung, Hyun-Chang Lim
Förderung
- Ministry of Science and ICT, South Korea
Zitieren
APA
Lim, H., Hong, J. Y., Shin, S. I., Chung, J. H., Thoma, D. S., Jung, R. E., & Lim, H. C. (2025). Effects of Polydeoxyribonucleotide ( PDRN ) on Endosinus Bone Regeneration Following Sinus Floor Elevation: An Experimental In Vivo Pilot Study. Clinical Oral Implants Research, 36(2), 239-249. https://doi.org/10.1111/clr.14378
Vancouver
Lim H, Hong JY, Shin SI, Chung JH, Thoma DS, Jung RE, et al. Effects of Polydeoxyribonucleotide ( PDRN ) on Endosinus Bone Regeneration Following Sinus Floor Elevation: An Experimental In Vivo Pilot Study. Clinical Oral Implants Research. 2025;36(2):239-249. doi:10.1111/clr.14378
BibTeX
@article{Lim2025,
author = {Lim, Hyunwoo and Hong, Ji-Youn and Shin, Seung-Il and Chung, Jong-Hyuk and Thoma, Daniel S and Jung, Ronald E and Lim, Hyun-Chang},
title = {Effects of Polydeoxyribonucleotide ( PDRN ) on Endosinus Bone Regeneration Following Sinus Floor Elevation: An Experimental In Vivo Pilot Study},
journal = {Clinical Oral Implants Research},
year = {2025},
volume = {36},
number = {2},
pages = {239--249},
doi = {10.1111/clr.14378}
}
EUVIMED